Next Article in Journal
Chemoresistance in Pancreatic Cancer
Previous Article in Journal
The Endocrine Function of Osteocalcin Regulated by Bone Resorption: A Lesson from Reduced and Increased Bone Mass Diseases
Previous Article in Special Issue
Molecular and Cellular Bases of Immunosenescence, Inflammation, and Cardiovascular Complications Mimicking “Inflammaging” in Patients with Systemic Lupus Erythematosus
Open AccessArticle

BTLA Expression on Th1, Th2 and Th17 Effector T-Cells of Patients with Systemic Lupus Erythematosus Is Associated with Active Disease

1
Department of Nephrology, University Hospital Essen, University Duisburg-Essen, 45122 Essen, Germany
2
Department of Rheumatology and Clinical Immunology, Kliniken Essen-Mitte, 45239 Essen, Germany
3
Department of Infectious Diseases, University Hospital Essen, University Duisburg-Essen, 45122 Essen, Germany
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2019, 20(18), 4505; https://doi.org/10.3390/ijms20184505
Received: 31 July 2019 / Revised: 25 August 2019 / Accepted: 5 September 2019 / Published: 11 September 2019
An imbalanced T-cell homeostasis plays an important role in the pathogenesis of systemic lupus erythematosus (SLE). Co-stimulatory and co-inhibitory molecules regulate T-cell differentiation, survival, and cytokine production. B- and T-lymphocyte attenuator (BTLA) is a co-inhibitory molecule which negatively regulates T-cell activation. The aim of this study was to investigate BTLA expression on regulatory and effector CD4+ T-cells in SLE patients with and without lupus nephritis (LN) during active and inactive disease. Therefore, peripheral blood of forty-one SLE patients and twenty-one healthy controls (HC) was phenotypically analyzed. Next, ex vivo stimulated T-cells were analyzed for the expression of BTLA on Th1-, Th2-, and Th17-effector cells by flow cytometry. Renal involvement was defined as biopsy-proven LN. Disease activity was assessed by SLE disease activity index (SLEDAI). Percentages of peripheral unstimulated BTLA+ CD4+ T-cells were significantly decreased in SLE patients with active disease. However, ex vivo stimulated Th1, Th2, and Th17 effector T-cells, expressed increased percentages of BTLA expression in active disease. In contrast, the BTLA expression on CD4+CD25++CD127 regulatory T-cells was not significantly different. BTLA seems to be an important co-inhibitory molecule in the T-cell homeostasis of patients with systemic lupus erythematosus and crucial for disease activity. View Full-Text
Keywords: SLE; BTLA; Costimulation; IFN-γ; IL-10; IL-17A SLE; BTLA; Costimulation; IFN-γ; IL-10; IL-17A
Show Figures

Figure 1

MDPI and ACS Style

Oster, C.; Wilde, B.; Specker, C.; Sun, M.; Kribben, A.; Witzke, O.; Dolff, S. BTLA Expression on Th1, Th2 and Th17 Effector T-Cells of Patients with Systemic Lupus Erythematosus Is Associated with Active Disease. Int. J. Mol. Sci. 2019, 20, 4505.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map

1
Back to TopTop